Jim Cramer's Top Takeaways: United Therapeutics, American Airlines, Wix.com

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

UTHR Chart
UTHR data by YCharts

United Therapeutics (UTHR) : In an exclusive interview, Cramer sat down with Dr. Martine Rothblatt, chairman and co-CEO of United Therapeutics, the biotech with four drugs on the market treating pulmonary arterial hypertension.

Rothblatt explained that she first started United Therapeutics after her youngest daughter was diagnosed with a rare for of hypertension and given just three years to live. She said that thanks to their research and development, her daughter continues to survive by taking a pill just a few times a day, as compared to a 24-hour-a-day infusion pump, which was the course of treatment before United Therapeutics.

While pulmonary arterial hypertension is considered a rare disease, there are still over 30,000 patients in the U.S. alone that suffer from it. Rothblatt said that reaching those patients is critical and they've been accomplishing that through patient associations.

Even with the stock up 37.5% so far in 2015, Cramer thinks it's inexpensive given this company's fascinating story.

AAL Chart
AAL data by YCharts

American Airlines (AAL) : Cramer also sat down with Doug Parker, chairman and CEO of American Airlines (AAL) , the airline that's now trading at just five times earnings.

Parker defended his decision to take his salary in American Airlines stock by saying that the industry has changed and there's real business out there and his company's stock is once again a real currency to be proud of.

But even with business improving, Parker admitted that some airlines are adding flights in excess of demand, causing pockets of increased competition. It's nothing like the past, he noted, but American stands ready to compete where needed.

Finally, when asked about currency pressures, Parker said that while a strong U.S. dollar hurts overseas earnings, it also lowers fuel prices, which averages out to a gain for American.

WIX Chart
WIX data by YCharts

Wix.com (WIX) : In his third exclusive interview, Cramer also sat down with Avishai Abrahami, co-founder, chairman and CEO of Wix.com (WIX) , the Web site hosting provider that raised its full-year guidance two weeks ago, sending its shares up 20% so far this year.

Abrahami explained that when you want to build a Web site, you can either do it yourself from scratch, hire someone else, or use Wix, which makes it super simple and costs only $9 a month to get started. He continued that Wix makes money when customers upgrade to premium sites and services that offer more storage and bandwidth and applications such as ecommerce.

Wix has been growing mainly through word of month, Abrahami noted, with over half of new customers coming from the recommendations of others. Wix currently boasts over 63 million customers with over nine million mobile Web sites.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

If you liked this article you might like

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

United Therapeutics Gets a Quantitative Upgrade

United Therapeutics Gets a Quantitative Upgrade

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions